

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: María-Victoria Mateos Manteca

eRA COMMONS USER NAME (credential, e.g., agency login)

POSITION TITLE: Consultant Physician in Hematology, Associate Professor of Medicine and Director of the Myeloma Program

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Valladolid, Spain	MD	06/1993	Medicine
University of Salamanca, Spain		12/1997	Hematologist
University of Salamanca, Spain	Ph.D.	06/2001	Medicine

A. Personal Statement

I have the expertise, leadership, training, expertise and motivation necessary to successfully carry out the proposed research project. I have a broad background in clinical research in myeloma and plasma cell disorders, with specific expertise in the design of clinical trials in plasma cell disorders as well as in its coordination, data analysis and dissemination of the data. My research includes basically clinical research in plasma cell disorders, including MGUS, SMM and MM. I act as PI of different clinical trials at national or international level and this clinical research is complemented with funding for doing translational research on several regional, national and international-funded grants. In addition, one of my strengths is the ability for networking with other researchers and I am one of the chairs of the Spanish myeloma group being able to engage to the investigators at national level for, not only recruiting patients in the clinical trials but also to collecting the different samples required for complementing the clinical research. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget. The current application builds logically on my prior work.

1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; Oct 1;108(7):2165-72
2. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomized trial. Lancet Oncol 2010 Oct;11(10):934-41.
3. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013 Aug 1;369(5):438-47.

B. Positions and Honors

Positions and Employment

1994-1997	Residency in Hematology, University Hospital of Salamanca, Spain
1998-1999	LAIR Foundation research fellow
2000-2002	Coordinator of clinical trials, Clinical Cancer Research Center of Salamanca, Spain
2002-	Consultant physician in Hematology, Hematology Department, Hospital Universitario de Salamanca, Spain
2004-	Associate Professor, Department of Medicine, Salamanca University, Salamanca, Spain

Other Experience and Professional Memberships

2008-	Member of the International Myeloma Working group
2010-	Member of the International Myeloma Society
2011-	Associate editor of Blood Cancer Journal and Hemasphere.
2012-	Member of the American Society of Hematology
2014-	Member of the European Hematology association
2015-	Board Member, International Myeloma Society
2016-	Member of the European Myeloma Network
2020-	Member of the Scientific Committee of European School of Hematology
2014-	Member of the steering committee of Hematology-Oncology Society
2014-2018	Member of the Scientific Committee for Plasma Cell Disorders at American Society of Hematology
2012-13	Member of the advisory board of Scientific Program Committee at European Hematology Association
2013-2016	Member of the Scientific Program Committee at European Hematology Association
2016-2019	Board Member of European Hematology Association
2021-	Elect President of the Spanish Society of Hematology

Honors English

2014	VI premio nacional de investigación oncológica “Maria Julia Castillo”, Granada. Spain
2016	Magistral lecture Antonio Raich, Santiago de Compostela, Spain
2019	Prize to Excellence in Research, Controversies in Multiple Myeloma (COMy)
2019	“Brian Durie Award” to excellence in Myeloma Research
2021	Prize “Best in class” to the best Myeloma Unit in Spain

C. Contribution to Science

My areas of interest include multiple myeloma, the biology of plasma cells and new drugs development.

I led the first trial in which bortezomib was combined with melphalan and prednisone based on the preclinical studies conducted at the lab. This combination has been a standard of care that was subsequently optimized by the addition of the monoclonal antibody daratumumab. I also led globally this research, and daratumumab plus VMP is the approved combination in our country. In addition, I led the optimization of the use of bortezomib once per week instead of twice a week in the elderly MM patients, the weekly use of carfilzomib and have been the global principal investigator to show how the monoclonal antibody daratumumab can be used subcutaneously instead of intravenously with an impact in the quality of patients' life.

In the smoldering myeloma disease, I contributed to the development of the Spanish Risk model for the identification of high-risk smoldering and also led the first phase 3 clinical trial in high risk asymptomatic myeloma patients demonstrating a significant benefit in outcome for patients who received early treatment. I also was the global principal investigator to generate a new risk model (2/20/20) endorsed by the International Myeloma Working Group.

I am currently leading the introduction of mass spectrometry in the clinical trials conducted in the Spanish Myeloma Group as complementary technique for the response evaluation in Myeloma and I have also contributed to the establishment of minimal residual disease as a relevant prognostic marker in Myeloma.

Complete List of Published Work in MyBibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/maria%20victoria.mateos%20manteca.1/bibliography/public/>

D. Additional Information: Research Support and/or Scholastic Performance

Completed research support

- | | | |
|--|--------------------|-----------|
| 140/A/07 | PI: MV Mateos | 2007-2009 |
| Tratamiento con lenalidomida (Revlimid) y dexametasona en pacientes con mieloma múltiple quiescente con alto riesgo de progresión a mieloma múltiple sintomático: cambios en el sistema inmune y en el perfil de expresión génica. | | |
| Entidad: Junta de Castilla y León | | |
| GRS 1340/A/16 | PI: MV Mateos | 2007 |
| Papel de la vitamina D en el mieloma múltiple: implicaciones clínico-biológicas. | | |
| Entidad: Gerencia Regional de Salud de Castilla y León | | |
| GRS 1586/A/17 | PI: MV Mateos | 2017 |
| Caracterización biológica de la inmunoparesia e impacto pronóstico de su recuperación en pacientes con mieloma múltiple no candidatos a trasplante | | |
| Entidad: Gerencia regional de Salud | | |
| PI15/02049 | PI: MV Mateos | 2016-2018 |
| Evaluación ultra-sensible de enfermedad mínima residual como biomarcador de curabilidad en dos modelos de mieloma múltiple (sintomático y quiescente de alto riesgo) | | |
| Entidad: FIS | | |
| PI18/01673 | PI: MV Mateos | 2019-2021 |
| Caracterización y seguimiento del sistema inmune en pacientes mayores con MM tratados dentro del ensayo GEM2017FIT: tratando de personalizar el tratamiento para maximizar la respuesta | | |
| Entidad: Instituto de Salud Carlos III | | |
| GRS1849/A/18 | PI: MV Mateos | 2019 |
| Valor pronóstico de las alteraciones del cromosoma 1(ganancias de 1q y deleciones de 1p) en pacientes con mieloma múltiple de nuevo diagnóstico no candidatos a trasplante autólogo de progenitores hematopoyéticos | | |
| Entidad: Gerencia Regional de Salud | | |
| GRS2066/A/19 | PI: MV Mateos | 2020 |
| Estudio de los mecanismos implicados en la resistencia al anticuerpo monoclonal daratumumab en mieloma múltiple | | |
| Entidad: Gerencia Regional de Salud | | |
| GRS 2170/A/2020 | PIs: MV / MT Paíno | 2021 |
| Papel de la arginasa en la inmunosupresión en el Mieloma Múltiple: estudio de la combinación del inhibidor de arginasa INCB001158 con el anticuerpo monoclonal daratumumab | | |
| Entidad: Gerencia Regional de Salud de Castilla y León | | |

Ongoing research support

GCB
Towards New Efficacy Paradigms in Newly Diagnosed Multiple Myeloma (NDMM) Patients:
A Phase III GEM/PETHEMA Trial Project to Comparing the Current International Standard
VRD [VRD (X 6) + Plus Transplant and Consolidation (VRDx2)] Vs. an Extended VRD (x18 Cycles)
Including also Transplant, and Early Redirecting of 1st Line to Alternative Therapy if Unfavorable
Response Kinetic is Observed
Entidad: Asociación Española contra el Cáncer

PI21/01917
Análisis ultra-sensible y mínimamente invasivo de la enfermedad mínima residual en sangre periférica en
pacientes con mieloma múltiple
Entidad: Instituto de Salud Carlos III

SAMPLE